IL-1 Blockade in Acute Myocardial Infarction (VCU-ART3)

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified September 2013 by Virginia Commonwealth University
Information provided by (Responsible Party):
Virginia Commonwealth University Identifier:
First received: September 4, 2013
Last updated: September 20, 2013
Last verified: September 2013

VCU-ART3 is a double-blind randomized clinical trial of anakinra high dose vs anakinra standard dose vs placebo in patients with ST-segment elevation myocardial infarction (STEMI) measuring the effects on the acute rise and fall of the plasma C reactive protein levels during the first 14 days.

Condition Intervention Phase
Acute Myocardial Infarction
Drug: Anakinra 100 mg
Drug: Placebo
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Interleukin-1 Blockade With Anakinra in Patients With ST-segment Elevation Myocardial Infarction - the Virginia Commonwealth University Anakinra Remodeling Trial 3

Resource links provided by NLM:

Further study details as provided by Virginia Commonwealth University:

Primary Outcome Measures:
  • Acute phase response (CRP levels) [ Time Frame: 14 days ] [ Designated as safety issue: No ]
    Placebo corrected difference in the area-under-the-curve for CRP up to day 14

Secondary Outcome Measures:
  • Left ventricular end-systolic volume indices change [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    Placebo corrected interval change in left ventricular end-systolic volume indices over 12 months

  • Left ventricular ejection fraction [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    Placebo-corrected interval changes in left ventricular ejection fraction over 12 months

  • Heart Failure [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
    New onset of heart failure symptoms (NYHA II-IV)

Estimated Enrollment: 99
Study Start Date: October 2013
Estimated Study Completion Date: September 2016
Estimated Primary Completion Date: September 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Anakinra (standard dose)
Anakinra 100 mg daily for 14 days
Drug: Anakinra 100 mg
Anakinra 100 mg starting immediately and then every 24 hours
Drug: Placebo
Other Name: Placebo injections twice daily
Experimental: Anakinra (high dose)
Anakinra 100 mg twice daily for 14 days
Drug: Anakinra 100 mg
Anakinra 100 mg starting immediately and then every 24 hours
Drug: Anakinra 100 mg
Anakinra 100 mg starting 12 hours after first dose and then every 24 hours (so that Anakinra is given every 12 hours)
Placebo Comparator: Placebo
Placebo for 14 days
Drug: Placebo
Other Name: Placebo injections twice daily


Ages Eligible for Study:   21 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


In order to be eligible for this study, patients must meet ALL the 3 Inclusion criteria and NONE of the Exclusion criteria.

  1. Acute STEMI defined as chest pain (or equivalent) with an onset within 12 hours and ECG evidence of ST segment elevation (>1 mm) in 2 or more anatomically contiguous leads that is new or presumably new
  2. Planned or completed coronary angiogram for potential intervention
  3. Age>21


  • Inability to give informed consent
  • Pregnancy
  • Preexisting congestive heart failure (AHA/ACC class C-D, New York Heart Association III-IV)
  • Preexisting severe left ventricular dysfunction (EF<20%)
  • Preexisting severe valvular heart disease
  • Active infections (acute or chronic)
  • Recent (<14 days) or active use of anti-inflammatory drugs (not including NSAIDs or corticosteroids used for IV dye allergy only)
  • Chronic inflammatory disease (including but not limited to rheumatoid arthritis, systemic lupus erythematosus)
  • Known active malignancy of any type, or prior diagnosis in the past 10 years
  • Anticipated need for cardiac surgery
  • Active cancer (or prior diagnosis of cancer within the past 10 years)
  • Neutropenia (absolute neutrophil count<1,800/mm3)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01950299

Contact: Antonio Abbate, MD, PhD 804-828-0513
Contact: Benjamin W Van Tassell, PharmD 804-828-4583

United States, Virginia
Virginia Commonwealth University Not yet recruiting
Richmond, Virginia, United States, 23298
Contact: Antonio Abbate, MD, PhD    804-828-0513   
Principal Investigator: Antonio Abbate, MD, PhD         
Principal Investigator: Benjamin Van Tassell, PharmD         
Sponsors and Collaborators
Virginia Commonwealth University
  More Information

No publications provided

Responsible Party: Virginia Commonwealth University Identifier: NCT01950299     History of Changes
Other Study ID Numbers: VCU HM20000024
Study First Received: September 4, 2013
Last Updated: September 20, 2013
Health Authority: United States: Food and Drug Administration
United States: VCU-ART3 Data and Safety Monitoring Board

Additional relevant MeSH terms:
Myocardial Infarction
Myocardial Ischemia
Heart Diseases
Pathologic Processes
Cardiovascular Diseases
Vascular Diseases
Interleukin 1 Receptor Antagonist Protein
Antirheumatic Agents
Therapeutic Uses
Pharmacologic Actions processed this record on July 20, 2014